Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 114 results for embolism

  1. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA179

  2. Endovascular stent insertion for intracranial atherosclerotic disease (HTG288)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

    HealthTech guidance
    Published
    23 July 2012
    View recommendations

    Sections for HTG288

  3. Research into the long-term treatment effects of rivaroxaban is needed.

    details Comes from guidance Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287

    Research recommendation
    Published
    9 June 2015

  4. Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be conducted.

    thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Number TA261 Date issued July 2012 Other details

    Research recommendation
    Published
    9 June 2015

  5. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    Comes from guidance Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275

    Research recommendation
    Published
    9 June 2015

  6. During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    Comes from guidance Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275

    Research recommendation
    Published
    10 August 2021

  7. Further research should be in the form of randomised controlled trials or registries. It should report:

    Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism Number IPG778 Date issued November 2023 Other

    Research recommendation
    Published
    11 January 2024

  8. Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  9. Duration of prophylaxis for elective total hip replacement surgery:- What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  10. Effects of HRT on venous thromboembolism risk:- How does the preparation of HRT affect the risk of venous thromboembolism (VTE)?

    An increase in the risk of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) is a significant side effect of HRT, particularly...

    Research recommendation
    Published
    11 December 2015

  11. Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  12. Atrial fibrillation (QS93)

    This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    7 February 2018
    View quality statements

    Sections for QS93

  13. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and diagrams...

  14. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 9-11 for more information and diagrams...

  15. Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018